Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 68, Issue 1, Pages 218-228
Publisher
Wiley
Online
2015-08-28
DOI
10.1002/art.39407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
- (2015) Grant S. Schulert et al. Annual Review of Medicine
- Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-γ
- (2015) Karen Put et al. RHEUMATOLOGY
- 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C
- (2015) Sarah Ringold et al. ARTHRITIS AND RHEUMATISM
- Macrophage activation syndrome and cytokine-directed therapies
- (2014) Grant S. Schulert et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome
- (2014) Masafumi Kobayashi et al. Modern Rheumatology
- Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model
- (2014) Claudia Bracaglia et al. Pediatric Rheumatology
- Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
- (2014) Fabrizio De Benedetti et al. Pediatric Rheumatology
- 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among C
- (2014) Sarah Ringold et al. ARTHRITIS CARE & RESEARCH
- Genetic Defects in Cytolysis in Macrophage Activation Syndrome
- (2014) Mingce Zhang et al. Current Rheumatology Reports
- Interferon-γ Mediates Anemia but Is Dispensable for Fulminant Toll-like Receptor 9-Induced Macrophage Activation Syndrome and Hemophagocytosis in Mice
- (2013) Scott W. Canna et al. ARTHRITIS AND RHEUMATISM
- Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome
- (2013) P. J. KAHN et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6
- (2012) Masaki Shimizu et al. CYTOKINE
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Nicolino Ruperto et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Fabrizio De Benedetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: Implication for the pathogenesis of macrophage activation syndrome
- (2011) Raffaele Strippoli et al. ARTHRITIS AND RHEUMATISM
- A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features
- (2011) Nicolino Ruperto et al. ARTHRITIS AND RHEUMATISM
- Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH
- (2011) K. Zhang et al. BLOOD
- An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
- (2011) S. DAVI et al. JOURNAL OF RHEUMATOLOGY
- Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions
- (2011) Elizabeth D. Mellins et al. Nature Reviews Rheumatology
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
- (2010) P. Quartier et al. ANNALS OF THE RHEUMATIC DISEASES
- Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series
- (2010) Peter A. Nigrovic et al. ARTHRITIS AND RHEUMATISM
- Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients
- (2010) P. M. Miettunen et al. RHEUMATOLOGY
- Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis
- (2010) M. Shimizu et al. RHEUMATOLOGY
- Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin
- (2009) Andreea Coca et al. CLINICAL IMMUNOLOGY
- Anakinra for Systemic Juvenile Arthritis
- (2009) Andrew Zeft et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis
- (2009) Sebastiaan J. Vastert et al. RHEUMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started